Hydroxycarbamid Hikma (Hydroxycarbamide)

Hydroxycarbamide, the active ingredient in Hydroxycarbamid Hikma, is an antimetabolite (ribonucleotide reductase inhibitor) presented as an oral dosage form for oral use. It treats certain hematologic malignancies and disorders such as chronic myelogenous leukemia, polycythemia vera, essential thrombocythemia, and sickle cell disease.

GNH USA supplies Hydroxycarbamid Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Hydroxycarbamid Hikma is used in the management of hematologic disorders that involve abnormal cell proliferation.

- Chronic myelogenous leukemia: reduces leukemic cell growth and improves survival. - Polycythemia vera: controls elevated red blood cell mass and reduces thrombotic risk. - Essential thrombocythemia: lowers platelet count and mitigates vascular complications. - Sickle cell disease: decreases the frequency of vaso‑occlusive crises and related pain episodes.

Hydroxycarbamide may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Vomiting: occasional episodes after dosing. - Diarrhea: loose stools that may be transient. - Fatigue: generalized tiredness. - Hair loss: thinning or shedding of scalp hair. - Abdominal pain: cramping or discomfort.

Serious or Rare Side Effects: - Bone marrow suppression: leading to anemia, leukopenia, or thrombocytopenia. - Severe infection: due to reduced white blood cell counts. - Liver toxicity: elevated transaminases or hepatitis. - Allergic reactions: rash, pruritus, or anaphylaxis. - Secondary malignancies: rare risk of new cancers developing.

Before initiating therapy, several safety considerations should be addressed.

- Monitor blood counts: perform regular CBC to detect marrow suppression. - Assess renal function: adjust dosing in patients with impaired kidneys. - Evaluate hepatic function: check liver enzymes prior to and during treatment. - Pregnancy risk: category D; avoid use in pregnant women unless clearly needed. - Contraception: advise effective birth control for both sexes during therapy. - Store at below 25°C: keep in the original container, protect from moisture and direct sunlight.

Hydroxycarbamide can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Allopurinol: may increase risk of severe bone‑marrow suppression. - Live vaccines: immunosuppression can reduce vaccine efficacy and increase infection risk. - Other myelosuppressive agents (e.g., azathioprine, cyclophosphamide): additive suppression of blood cells.

Moderate Interactions (Monitor Closely): - NSAIDs: heightened gastrointestinal irritation. - Penicillins: possible reduction in hydroxycarbamide effectiveness. - Antacids containing aluminum or magnesium: may affect drug absorption. - CYP enzyme modulators: can alter plasma concentrations modestly.